Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51

Benzinga · 5d ago
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.